Data support BreezeBio’s hydrophilic nanoparticle mRNA-based approach for targeteddelivery to antigen-presenting cells and induction of immune tolerance BRISBANE, Calif., June 9, 2026, BreezeBio, Inc., formerly known as GenEdit, today announced data presented at the 2026 Scientific Sessions of the American Diabetes Association® (ADA) supporting its NanoGalaxy® hydrophilic nanoparticle platform for antigen-specific immune tolerance in type […] The post BreezeBio Presents Data Supporting NanoGalaxy® Platform for Antigen-Specific Immune Tolerance in Type 1 Diabetes at ADA 2026 first appeared on B
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules